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Objective: To assess the burden of renal cell carcinoma (RCC) in epidemiologic and eco-
nomic terms.
Methods: Retrospective, naturalistic longitudinal study on the occurrence, outcomes and
cost of RCC using an administrative database.We selected residents of Friuli-Venezia-Giulia
(FVG), a North-eastern Region of Italy, who had a RCC first hospital admission during the
period 2000–2004, and we followed them up until: 30th June 2005, death or transfers. Direct
medical costs were quantified in the perspective of FVG Regional Health Service.
Results: We enrolled 1358 patients (63% male), the 18.8% presenting a metastatic-stage,
leading to a crude incidence of 23/100.000 person-years. During the follow-up, 76% of the
metastatic patients and 21% of the non-metastatic patients died.Total health care costs
per-patient over the maximum of follow-up were 16,090€ for the localised stage group
and 17,656€ in the metastatic-stage group.
Discussion: RCC imposes a significant epidemiologic and economic burden to the health-
care-system and the society.
 2008 Elsevier Ltd. All rights reserved.1. Introduction and scope
The measurement of the burden of disease is a topic of peren-
nial interest to public health researchers and policy makers.
These measures are used to describe the general state of
health of the population and to establish public health goals,1
to compare national health status and the performance of
health systems across countries,2 to assess the allocation of
health care and health research resources across disease cat-er Ltd. All rights reserved
fax: +39 081678658.
Mantovani).egories, and to evaluate the potential costs and benefits of
public health interventions.
Traditional measures of disease burden are well estab-
lished, although the acquisition of data to synthesise these
measures is still far from optimal in many national, regional
and local jurisdictions. Coremeasures include disease-specific
incidence, prevalence, mortality and, in some cases, years of
potential life lost. These parameters tend to be relatively
straightforward, unidimensional and ‘objective’, whereas
newer, more conjectural measures tend to incorporate an.
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cost of illness (COI), where the evaluative components are
the economic cost associated with treating illness (also called
cost of care) and the economic value attributed to the loss of
health and life. The COI methodology, established by Rice
et al.,3 has long been accepted as a descriptive measure of
the burden of disease. COI estimates typically include three
main elements: direct cost, morbidity cost and mortality cost.
Often direct cost is measured by expenditures formedical pro-
cedures and services provided for the treatment and care for
the disease: this is also called cost of care; morbidity cost is
measured by lost income due to thework disability and absen-
teeism associatedwith the disease entity andmortality cost is
measured as lost income associated with premature death.
The estimation of the direct medical costs for specific dis-
eases is, increasingly, an important area of health services re-
search. Policy makers need cost estimates to rationally
allocate health care resources at a time when the main objec-
tives, in many countries, are to contain costs as well as to im-
prove the quality and quantity of care. The rigorous
estimation of the direct medical costs can inform consider-
ation of the cost effectiveness of alternative policies and
interventions. Until fairly recently, most estimates of the di-
rect medical costs fell within the type of ‘cost-of-illness’ stud-
ies, which tend aggregate expenditures per annum per
disease category.
There has been an increasing demand for more detailed
disease-specific estimates of the direct medical costs derived
from patient-level longitudinal expenditures that occur over
the entire course of life of a diseased individual. Such data
can be used to build several policy-relevant indicators, e.g.
the long-term cost from diagnosis until death, the cost per
person-year lived with a disease, and the costs for the initial,
continuing and terminal phases of cancer care. These phase-
specific costs can be used to assess the efficiency, i.e. cost to
effect ratio, of alternative treatments and disease manage-
ment programmes.
Long-term costs are useful in assessing the cost effective-
ness of preventive strategies. Costs per person-year can be
used to adjust capitation rates and budgets on the basis of
risk, and also to assess the ‘burden’ of a disease when setting
broad priorities for research and public health programmes.
Renal cell carcinoma (RCC) is diagnosed in more than
120.000 patients in Europe and USA every year and causes
about 60.000 deaths.4 It represents about 85% of kidney can-
cer5 which accounts for about 3% of all adult malignancies,
RCC is the most lethal of the urologic cancers.6
Patients are often first diagnosed when already in ad-
vanced stages of the disease, with 40–50% of them having
unrespectable or metastatic form of the disease.7,8
Despite recent advances in treatment options with the
emergence of new experimental therapies, the prognosis for
long-term survival remains low, with or without therapy9:
the 5-year survival rate for patients with stage IV renal cell
carcinoma (around 1/3 of total patients) ranges from 5% to
10%8 and a further 20–30% of patients with initially localised
disease relapse after nephrectomy.10
Treatment options for patients with localised stage cancer
include: radical or partial nephrectomy, radiofrequency abla-
tion and cryosurgery, all of which frequently lead to cure.However, patients with advanced RCC historically have had
limited treatment options, considering the limited effective-
ness and the associated severe side-effects of cytokine immu-
notherapy and chemotherapy.11
For about 25 years, immunotherapy with interferon a (IFN-
a) and interleukin 2 (IL-2) has represented the basis of the
treatment for metastatic RCC. During the last 3 years there
has been a dramatic increase in treatment options, as four
new drugs have received regulatory approval: sorafenib, sun-
itinib, temsirolimus and bevacizumab.12
Despite the growing importance of RCC, data on its eco-
nomic burden are sparse and rare.
Kidney cancer imposes a significant burden on health care
systems due to: advanced diagnostic radiological test, high
cost of treatment that often involves in surgery, hospitalisa-
tion, regular surveillance and visits to assess recurrence.13
This study is aimed to evaluating simultaneously frequency
of occurrence, outcomes and cost of care of RCC, thus provid-
ing empiric evidence on the burden of RCC.
2. Methods
2.1. Techniques
To this end a retrospective, longitudinal, naturalistic study
based on the claims of individuals enrolled in the Friuli Vene-
zia Giulia (FVG) administrative database was performed.
FVG Regional Health Authority (RHA) is in charge of uni-
versal healthcare coverage of all the residents of FVG, a region
of approximately 1.2 million inhabitants in the north-eastern
Italy.
The analysis was carried out from the perspective of FVG
Regional Health Service.
For the purpose of this study, hospital admissions, outpa-
tient care, drug prescriptions and mortality databases were
used and patients were identified followed longitudinally by
means of an alphanumeric code that univocally identifies
each enrollee of the FVG-RHA.
2.2. Study population
The source population for this study were FVG residents be-
tween 1996 and 2006. Membership to the study population
was the occurrence of the first hospital admission event with
diagnosis of RCC (ICD9 code 189) during the period between
1st January 2000 and 31st December 2004. The date of RCC
diagnosis was considered as the index date, i.e. the date of
inclusion in the study population. In order to be able to iden-
tify incident cases and to follow them up, individuals with
diagnosis of cancer (ICD9 code 140–239) in the years 1996–
1999 and patients coming from other Regions were excluded
from our analysis.
2.3. Observation period
Enrolled patients were followed up starting from index date
up to the occurrence of 30th June 2005, death, or withdrawal
from the RHA (i.e. transfer out of the Region), whichever come
first.
Therefore, the individual length of follow-up was variable.
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Demographic characteristics (age and gender) were collected
at baseline, whilst information on vital status, outpatient
care, drug prescription and hospital admission were collected
during the follow-up period.
Diagnosis related group (DRG) charges14 were applied to
estimate the cost of hospitalisations and drug prescriptions
information were obtained from the pharmaceutical database
that includes every prescription dispensed to outpatients by
the community pharmacies. Drug therapies were quantified
using market prices reported by the Italian National Thera-
peutic Formulary.15
Outpatient care database, including visits, diagnostic and
laboratory tests, was used to quantify resources absorption
whilst costs were calculated by means of ambulatory tariffs.16
Survival and costs analyses were performed considering
the presence or the absence of metastases. The disease was
considered at the metastatic-stage at diagnosis if the patient
had a hospital admission recording metastases (ICD-9 CM
196.xx, 197.xx, 198.xx) within a time window of 60 d (i.e.
either before or after) from the index date.
The crude incidence was calculated as the rate between
new cases and person time expressed as 100.000 person-
years.
All costs are expressed in Euros of 2005 and have been cal-
culated as the sum of all claims related to RCCs incident sub-
jects recorded after the index date.
Costs expressed as Euros per patient and further described
as the cost of the first year (i.e. 365 d from the index date) and
as total cost (i.e. all the follow-up period), because these can
be used for short and long-term planning needs of Health
Authorities.
2.5. Statistical analysis
Estimates of central tendency expressed by using means and
frequencies, and standard deviation was used as a measure of
dispersion
Kaplan–Meier estimates of survival according to the pres-
ence or absence of metastases were compared with the use
of a log-rank test. Univariate and multivariate analyses of sur-
vival with the use of the Cox proportional hazards method
were performed to obtain the hazard ratios for death and
associated 95% confidence intervals for the comparison be-
tween patients with and without metastases.Table 1 – Population characteristics
Variable With metastases Without metasta
Age (years) 69.8 66.7
Sex
Male 156 700
Female 100 402
256 1102
Length of follow-up (d) 382.14 857.81
Mortality 0.76 0.21
a Adjusted for age and sex.
b Hazard ratio.Point and interval estimates of differences between cases
with or without metastases were assessed resorting to a boot-
strap technique with 5000 samples. Mean costs differences
were subsequently estimated fitting a linear least squares
regression model adjusting for age and sex.
All analyses were performed using SPSS versions 15.0 soft-
ware (SPSS, Chicago, IL).
3. Results
During the study period (January 2000–December 2004) 1358
patients with diagnosis of RCC were enrolled (63% male),
the 18.8% of which presenting with a metastatic-stage
(mRCC), leading to a crude incidence of 23/100.000 person-
years.
Subjects with and without metastases were, on average,
69.9 and 66.8 years old, respectively, with a difference statis-
tically significant (Table 1).
During the period of observation, 195 subjects in the met-
astatic group died (76%) and 240 (21%) subjects in the group
without metastases.
As compared with RCC patients, mRCC patients had an in-
creased risk of death (hazard ratio 5.8, 95% confidence inter-
val 4.79–7.04; P < 0.0001). After adjustment for age and sex,
the hazard ratio associated with metastases was not signifi-
cantly affected by any of the baseline characteristics exam-
ined (Table 1).
The risk of death was significantly higher amongst meta-
static-stage patients with a median survival of about 6
months (Fig. 1).
Total health care costs per patients over the maximum of
follow-up were 16,090 Euro for the localised stage group and
17,656 Euro in the metastatic-stage group (Table 2).
Inpatient payments were 11,424 Euro (71%) for RCC pa-
tients and 14,238 Euro (81%) for mRCC patients. Ambulatory
and diagnostic payments per patients were 2946 Euro (18%)
and 1986 Euro (11%) for RCC and mRCC patients, respectively.
The cost per patient related to the first year after diagnosis
for subjects with and without metastases was 13,692 and
10,502 Euro, respectively, with a mean difference of 3363 Euro
after adjusting for age and sex (Table 3). Considering subse-
quent years, differences between the two groups raised to
5900 Euro.
The vast majority of the total costs estimated either in the
first year after diagnosis and during the entire follow-up can
be attributed to hospital care (Tables 2 and 3).ses Difference/OR/(95% CI) Difference/OR/(95% CI)a
–3.1 (–4.63/–1.46)
1.12 (0.84/1.47)
475.66 (409.57/541.56)
5.8 (4.79/7.04)b 5.5 (4.52–6.64)b
Fig. 1 – Kaplan–Meier survival curves of individuals with diagnosis of RCC with and without metastases.
Table 2 – Cost per patient during entire follow-up period
Variable With metastases (N = 256) W/O metastases
(N = 1102)
Difference (95% CI) Difference (IC 95%)a
Cost of hospitalisation 14238.30 11424.69 2813.61 (1112.47/4514.76) 2928.97 (1326.35/4531.58)
Cost of drugs 1431.34 1719.29 –287.96 (–673.42/97.51) –285.62 (–663.53/92.29)
Cost for outpatient care 1986.38 2946.36 –959.99 (–1744.41/–175.56) –817.14 (–1560.39/–73.89)
Total health care cost 17656.02 16090.35 1565.67 (–664.21/3795.55) 1826.20 (–223.72/3876.12)
a Adjusted for age and sex.
Table 3 – Cost per patient in the first year of follow-up
Variable With Metastases
(N = 256)
W/O metastases
(N = 1102)
Difference (95% CI) Difference (IC 95%)a
Cost of hospitalisation 11670.12 8859.47 2810.65 (1681.76/3939.54) 2920.42 (1872.69/3968.15)
Cost of drugs 875.38 597.52 277.86 (27.62/528.09) 283.28 (24.09/542.47)
Cost for outpatient care 1147.18 1045.36 101.83 (–229.11/432.76) 159.59 (–160.55/479.73)
Total health care cost 13692.68 10502.34 3190.34 (1857.88/4522.79) 3363.29 (2172.48/4554.11)
a Adjusted for age and sex
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This is the first study to assess occurrence, cost and outcomes
of RCC in the third party payer’s perspective in Italy and one
of the few ever performed.Results from our study show that, due to the large number
of hospitalisations and the high mortality, the epidemiologic
and socioeconomic burden to the healthcare-system and to
the society of RCC is high.
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tion of resources in the early phases after diagnosis, which is
true for patients with metastatic and without metastases at
diagnosis, and in the late stages of the disease. Given the lat-
ter is more common for mRCC than for RCC, especially in the
first year after diagnosis, this fact could explain the higher
costs incurred by mRCC patients than RCC patients in the
first year of follow-up. The cost of mRCC is in fact concen-
trated into a very short time window, given the often rapid
and fatal evolution of the disease, whereas the cost of RCC
is spread over a longer period of time in light of its more
favourable survival. Once referred to a homogeneous time
basis (e.g. one month), RCC patient’s costs are consistently
lower than those for mRCC as the latter die earlier than
the localised stage patients. To put figures into perspective,
the 17,656 Euro of total healthcare cost of an incident mRCC
individual are related to an average follow-up of almost 12.5
months (i.e. 382 d): therefore, the average monthly cost is
approximately 1400 Euro per patients per month. In contrast,
the 16,090 Euro of total healthcare cost of an incident non-
metastatic RCC individual are related to an average follow-
up of 28.5 months (i.e. 857 d); consequently the average
monthly cost is approximately 560 Euro per patients per
month. Therefore, it is both true that the cost per unit of
time (e.g. month) of mRCC is much (2.5 times) higher than
non-mRCC, and that, because of limited survival, the overall
cost is only slightly (10%) superior.
Hospital care represents themost important component of
health care resources utilisation for RCC. In fact, considering
the entire follow-up period, hospitalisation account for the
71% and 81% in the localised and metastatic-stage group,
respectively. This is mainly represented by surgical proce-
dures, which remain the standard of care for most stages of
the disease.
Despite the evidencewe presented is based onmore than 5
years observation of a source population of 1.2 million sub-
jects, with a study population of more than 1300 subjects
and measurements of real practice, actual resources absorp-
tion and cost directly borne by the third party payer, our study
has potential limitations.
First, direct costs other than those for hospitalisation, drug
therapy and diagnostic test could not be measured as they are
not reimbursed by the third party payer. This is likely to cause
an underestimate, though probably marginal, of the total bur-
den of care for RCC, as costs associated with the consumption
of nursing or other resources for personal care were not
available.
A second limit is the absence of information on indirect
cost, i.e. productivity loss, as well as intangible consequences,
such as health related quality of life impairment. This is likely
again to lead to an underestimate of the total burden. Any-
way, the impact of indirect cost on society is likely to be of
modest economic value, as indirect costs are expected to rep-
resent around 10% of total cost17: because of the age at onset,
most patients are likely to be already retired when the disease
is diagnosed.
Despite conservative, the results of this study exhibit a
considerable economic impact of RCC in FVG Region. Inter-
ventions able to prevent the presence of metastases at thetime of diagnosis have the potential to yield medical but also
considerable economic benefits.
Evidence from this study will be potentially beneficial to
estimate preventive strategies as well as different established
and new therapies, particularly in the metastatic and ad-
vanced phase of the disease, in which several new therapies
have recently become available.
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